FDA looks to modeling and simulation tools to streamline product reviews

The US Food and Drug Administration (FDA) recently published a report on how it uses modeling and simulation (M&S), highlighting the untapped opportunities to improve efficiency and predictability at the agency. Some of the key opportunities identified in the report are the need to develop guidelines for using such tools in the premarket setting and to harmonize how they are used among its product centers, international regulators and industry.